{
    "organizations": [],
    "uuid": "2bb774594277a4689cc641fd70460d3f04d17725",
    "author": "",
    "url": "https://www.reuters.com/article/brief-mylan-partners-with-fujifilm-kyowa/brief-mylan-partners-with-fujifilm-kyowa-kirin-biologics-idUSFWN1RO0GF",
    "ord_in_thread": 0,
    "title": "BRIEF-Mylan Partners With Fujifilm Kyowa Kirin Biologics",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 12 AM / Updated 24 minutes ago BRIEF-Mylan Partners With Fujifilm Kyowa Kirin Biologics Reuters Staff \n  Mylan NV: \n* MYLAN PARTNERS WITH FUJIFILM KYOWA KIRIN BIOLOGICS TO COMMERCIALIZE BIOSIMILAR TO HUMIRAÂ® (ADALIMUMAB) \n* MYLAN NV - COMPANIES EXPECT TO RECEIVE A DECISION FROM EMA IN SECOND HALF OF 2018 \n* MYLAN NV - FUJIFILM KYOWA KIRIN BIOLOGICS GRANTS MYLAN AN EXCLUSIVE LICENSE TO COMMERCIALIZE ADALIMUMAB BIOSIMILAR IN EUROPE \n* MYLAN NV - FUJIFILM KYOWA KIRIN BIOLOGICS IS ELIGIBLE TO RECEIVE A SUBSEQUENT COMMERCIALIZATION MILESTONE PAYMENT AND SALES ROYALTIES \n* MYLAN NV - FUJIFILM KYOWA KIRIN BIOLOGICS WILL RECEIVE AN UP-FRONT FEE UNDER DEAL \n* MYLAN NV -CO, FUJIFILM KYOWA KIRIN BIOLOGICS CONTINUE TO NEGOTIATE FOR COMMERCIALIZING PRODUCT IN ADDITIONAL TERRITORIES \n* MYLAN NV - UNDER AGREEMENT TERMS CO TO BE RESPONSIBLE FOR SALES ACTIVITY OF PRODUCT IN EUROPEAN COUNTRIES \n* MYLAN NV - CO, FUJIFILM KYOWA KIRIN BIOLOGICS EXPECT TO RECEIVE DECISION FROM EMA REGARDING MAA FOR PROPOSED BIOSIMILAR TO HUMIRA IN H2 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-04-11T14:10:00.000+03:00",
    "crawled": "2018-04-11T14:26:01.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "partner",
        "fujifilm",
        "kyowa",
        "kirin",
        "biologics",
        "reuters",
        "staff",
        "mylan",
        "nv",
        "mylan",
        "partner",
        "fujifilm",
        "kyowa",
        "kirin",
        "biologics",
        "commercialize",
        "biosimilar",
        "adalimumab",
        "mylan",
        "nv",
        "company",
        "expect",
        "receive",
        "decision",
        "ema",
        "second",
        "half",
        "mylan",
        "nv",
        "fujifilm",
        "kyowa",
        "kirin",
        "biologics",
        "grant",
        "mylan",
        "exclusive",
        "license",
        "commercialize",
        "adalimumab",
        "biosimilar",
        "europe",
        "mylan",
        "nv",
        "fujifilm",
        "kyowa",
        "kirin",
        "biologics",
        "eligible",
        "receive",
        "subsequent",
        "commercialization",
        "milestone",
        "payment",
        "sale",
        "royalty",
        "mylan",
        "nv",
        "fujifilm",
        "kyowa",
        "kirin",
        "biologics",
        "receive",
        "fee",
        "deal",
        "mylan",
        "nv",
        "fujifilm",
        "kyowa",
        "kirin",
        "biologics",
        "continue",
        "negotiate",
        "commercializing",
        "product",
        "additional",
        "territory",
        "mylan",
        "nv",
        "agreement",
        "term",
        "co",
        "responsible",
        "sale",
        "activity",
        "product",
        "european",
        "country",
        "mylan",
        "nv",
        "co",
        "fujifilm",
        "kyowa",
        "kirin",
        "biologics",
        "expect",
        "receive",
        "decision",
        "ema",
        "regarding",
        "maa",
        "proposed",
        "biosimilar",
        "humira",
        "h2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}